Alvogen Group

Alvogen is a pharmaceutical company that develops, manufactures, and markets a diverse range of products, including generic, brand, over-the-counter, and biosimilar medications. The company is committed to addressing various health conditions, with a particular focus on oncology, cardiology, respiratory health, neurology, and gastroenterology. Alvogen's offerings include oral dosage forms, soft gelatin capsules, modified release tablets, transdermal systems, creams, ointments, and injectables. By providing affordable generic medications, Alvogen aims to help reduce healthcare costs globally while promoting healthier and more active lives for patients.

Thor Kristjansson

Executive Vice President of M&A

Chris Young

Executive Vice President, Global Operations

Tunie Zaku

US CFO

7 past transactions

Alvotech

Venture Round in 2020
Alvotech is a specialty biopharmaceutical company dedicated to the development and manufacturing of high-quality biosimilar medicines. Founded in 2013 by Róbert Wessman in Reykjavík, the company aims to enhance patients' health and quality of life worldwide by increasing access to effective therapies for a range of ailments. Through its integrated approach, Alvotech focuses on providing proven treatments that address various diseases, thereby contributing to improved healthcare outcomes globally.

Kerecis

Series C in 2019
Kerecis specializes in developing patented fish-skin products designed to promote healing in humans. Utilizing Omega-3 fatty acids extracted from cold-water fish, their therapeutic offerings serve as effective substitutes for human skin, significantly aiding in the treatment of various wounds, including burns and diabetic ulcers, as well as applications in oral surgery, hernia repair, and breast reconstruction. The company's products are formulated to retain the natural properties of fish skin, minimizing disease-transfer risks while enhancing tissue regeneration. Kerecis has substantiated its technology through over 50 studies, including two double-blind, randomized control trials that demonstrated superior efficacy compared to traditional mammalian-based treatments. The organization continues to expand its product range to address diverse medical needs across multiple surgical domains.

Omega Bittner

Acquisition in 2017
Omega Bittner, a subsidiary of Perrigo Company plc, is a pharmaceutical company based in Moscow, Russia, founded in 1987. The company specializes in the distribution and manufacturing of homeopathic medicinal products, offering a targeted portfolio of over-the-counter drugs. Its product range includes treatments primarily in women’s healthcare and cough and cold remedies, as well as medications for cold, flu, and heart-related issues.

OOO Dolfin

Acquisition in 2016
OOO Dolfin manufactures anti-inflammatory, immunomodulatory, antiseptic agent for infections.

County Line Pharmaceuticals

Acquisition in 2016
County Line Pharmaceuticals, founded in 2007 by a team of experienced pharmaceutical executives, specializes in the manufacture of generic pharmaceutical products. This team previously held significant roles at Schwarz Pharma Inc. and contributed to the establishment of Kremers Urban, a notable generic subsidiary. County Line Pharmaceuticals offers a diverse range of products, including oral medications, creams, ointments, gels, and orally disintegrating tablets, aiming to provide accessible and effective healthcare solutions.

Dream Pharma Corp

Acquisition in 2014
Dream Pharma Corp., pharmaceutical company, manufactures prescription and OTC medications in South Korea. It offers tablets, capsules, creams, injections, and powders in the areas of antihistamines, pain, gastrointestinal, respiratory, circulatory, dermatology, anti-obesities, and others; and nutritional dietary supplements. The company exports its products to India and Vietnam; and offers its products through partnerships with pharmaceutical companies in the United States, Asia, and Europe. Dream Pharma Corp. was formerly known as H-Pharm Co., Ltd. and changed its name to Dream Pharma Corp. in January 2005. The company was founded in 1995 and is based in Seoul, South Korea. Dream Pharma Corp. operates as a subsidiary of Hanwha Corp.

Labormed

Acquisition in 2012
LaborMed's initial focus was on building its portfolio of cardiovascular and central nervous systems treatments.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.